biotech · Acute Myeloid Leukemia · Acute Myelogenous Leukemia in Relapse · APTOF
Aptose Biosciences
Aptose Biosciences is a biotech organization headquartered in San Diego, USA. It trades on NYSE under ticker APTOF. Primary therapeutic focus areas include Acute Myeloid Leukemia, Acute Myelogenous Leukemia in Relapse, C
Company details
- Status
- Public
- HQ
- San Diego, USA
- Founded
- 2014
- Employees
- 32
- Programs
- 8
- Drugs
- 1
- Patents
- 7
LOR-253 HCl
Phase 1 · small molecule · Advanced or Metastatic Solid Tumours
LOR-253 HCl for Advanced or Metastatic Solid Tumours is a Phase 1 program (small_molecule) at Aptose Biosciences with 1 ClinicalTrials.gov record(s).
Internal code 253-SOL1-01
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Aptose Biosciences
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Advanced or Metastatic Solid Tumours
- Status
- completed
- Trials
- 1